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Abstract
Background: Stroke is a major cause of morbidity and mortality, especially in low and middle income countries. Medical
management is the mainstay of therapy to prevent recurrence of stroke. Current estimates are that only 1 in 6 patients
have perfect adherence to medication schedules. Using SMS (Short Messaging Service) as reminders to take medicines
have been used previously for diseases such as diabetes and HIV with moderate success. We aim to explore the
effectiveness and acceptability of SMS in increasing adherence to medications in patients with stroke.
Methods: This will be a randomized, controlled, assessor blinded single center superiority trial. Adult participants with
access to a cell phone and a history of stroke longer than 1 month on multiple risk modifying medications will be selected
from Neurology and Stroke Clinic. They will be randomized into two parallel groups in a 1:1 ratio via block technique with
one group receiving the standard of care as per institutional guidelines while the parallel group receiving SMS reminders for
each dose of medicine in addition to the standard of care. In addition intervention group will receive messages for lifestyle
changes, medication information, risk factors and motivation for medication adherence. These will bemodeled on Social
Cognitive Theory and Health Belief Model and will be categorized by Michies Taxonomy of Behavioral Change
Communication. Patient compliance to medicines will be measured at baseline and then after 2 months in each group by
using the Morisky Medication Adherence Scale. The change in compliance to medication regimen after the intervention
and the difference between the two groups will be used to determine the effectiveness of SMS reminders as a tool to
increase medication compliance. The acceptability of the SMS will be determined by a tool designed for this study whose
attributes are based Rogers Diffusion of innovation theory.
A sample size of 86 participants in each arm will be sufficient to detect a difference of 1 point on the MMAS with a power
of 90 % and significance level of 5 % between the two groups; using an attrition rate of 15 %, 200 participants in all will be
randomized.
Discussion: The SMS for Stroke Study will provide evidence for feasibility and effectiveness of SMS in improving post stroke
medication adherence in an LMIC setting.
Trial registration: https://clinicaltrials.gov/ct2/show/NCT01986023 11 /11/2013
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Background
Stroke is a major cause of death and disability worldwide
that affects 16 million persons annually [1]. The burden
is especially high in low and middle income countries
which account for more than 85 % of all stroke related
mortality [2, 3]. Pakistan is no different, with a lifetime
stroke prevalence of 19 % and a recurrence risk of 53 %
in the first year alone [4–7].
Long term mortality due to stroke is most frequently re-
lated to cardiovascular disease (cerebrovascular or heart
disease) [8, 9]. Predictors include diabetes mellitus, atrial
fibrillation, large artery atherosclerosis and ischemic heart
disease [10–14], all of which are modifiable through med-
ical management. Effective therapy for stroke hence com-
prises of a combination of antiplatelet, anti-lipid and
antihypertensive therapy [15]. For medical management to
be effective however, compliance to medication schedule
is the single most important factor.
Current estimates are that only one sixth of all patients
come close to perfect adherence to their medication regi-
men [16]. The issue is gaining importance due to an in-
crease in the prevalence of chronic diseases and an aging
population [17]. Common causes of medication non adher-
ence include complex treatment regimens [18] and patient's
lack of belief in the treatment [19]. Practical ways to im-
prove medication adherence are still not well established.
Strategies that have previously shown success include tele-
phone calls, behavior therapy and dissemination of informa-
tion materials relating to adherence [20–22]. These
interventions however are often complex and require abun-
dant resources which make them impractical in resource
strapped regions [20]. Using innovation and technology of-
fers alternative solutions that may also be able to address
the issue of cost and resources. One such solution is the use
of the Short Text Message system (SMS). In the last 10 years,
there has been an exponential increase in the use of mobile
phones in Pakistan. There are currently more than 132 mil-
lion active mobile phone connections in the country as
compared with a little over 5 million in 2004 [23]. This
translates to around 77 % of all Pakistanis [23] having access
to a cell phone today and with it, SMS. The rise has been
due to extremely affordable costs. An SMS in Pakistan costs
around 0.27 cents [24]. Use of SMS is thus a potential tool
in aiding patients adhere to medication schedules.
SMS has been used previously in diseases such as asthma,
HIV and diabetes with variable success [25–36]. However,
to the best of our knowledge, tailored SMS for each patient
based on their dosing frequency, have not been studied be-
fore. Moreover SMS to promote health, that are informed
by Health Theory and coded by Taxonomy for replicability,
are new and in line with developing the science of informed
replicable mHealth interventions [37].
We hypothesize that sending SMS as medication re-
minders for each dose and promoting healthy behavior will
improve medication adherence among stroke patients This
trial therefore aims to assess this effect of SMS on patient
compliance to medication, by customizing the SMS fre-
quency for each individual according to his/her dosing fre-
quency. The secondary objective is to assess the acceptability
and patient satisfaction associated with this intervention.
The trial will also attempt establish if an intervention like
this is cost effective in a low and middle income setting.
Methods
Design overview (Fig. 1 (Study flow chart))
The SMS4stroke trial will be a randomized, controlled,
assessor blinded single center superiority trial. The par-
ticipants will be randomized into two parallel groups in
a 1:1 ratio via block technique with one group receiving
the standard of care as per institutional guidelines while
the parallel group receiving SMS reminders for each
dose of medicine in addition to the standard of care.
The intervention group will also receive twice weekly
SMS that reinforce healthy behaviors and the import-
ance of taking medications.
Study setting
The trial will be conducted in the Neurology & Stroke Clinic
at the Aga Khan University Hospital (AKUH), Karachi,
Pakistan. The center is a Joint Commission International Ac-
creditation (JCIA) accredited tertiary care hospital located in
Karachi, a large metropolitan city located in the south of
Pakistan. Stroke service is delivered through a 24 h emer-
gency neurovascular team and ambulatory care clinics. The
Fig. 1 Study Flow Chart
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hospital caters to a large and diverse population with an esti-
mated 100 patients attending Neurology & Stroke Clinic
each day. The average annual stroke clinic volume is 1500
patient visits. The center also has logistic and technical ex-
pertise available from dedicated research support staff and
an independent Clinical Trials Unit (CTU) and a dedicated
Aga Khan Development Network e-Health Resource Center.
Participants
Participants will be selected from patients who present
to the Neurology and Stroke Clinic at the center.
Inclusion criteria
 Age greater than 18 years old
 History of stroke(s) confirmed by neuroimaging at
the time of the episode
 >1 month since last episode of stroke
 Use of at least two drugs such as (but not limited
to) anti platelets, statins, anti-hypertensives to con-
trol risk factors of stroke.
 Modified Rankin Score of 3 or less.
 Possession of a personal cell phone that the patient
has access to at all times. In the case of patients who
do not own or are unable to use mobile phones,
they must have a caregiver available at all times who
possesses a cell phone.
 Ability to receive, comprehend and reply to an SMS in
English, Urdu or Roman Urdu. In the case of patients
who themselves are unable to receive, comprehend or
reply to an SMS, they must have caregivers available at
all times who could perform the above mentioned tasks.
In addition all participants will be required to provide a
written, informed consent prior to enrollment Additional
file 1.
Exclusion criteria
 Biological impairment in reading or responding to
SMS such as (but not limited to) loss of vision,
visual field cuts, aphasia.
 Diagnosed organ dysfunction or malignancy such as
liver failure, renal dysfunction etc. that require
frequent medication changes.
 Plans to travel outside the country inside the two months
following enrollment and during SMS intervention
with a SIM unable to receive text messages.
Interventions
Control group
In the control group, patients will receive the usual
standard of care provided at the center for stroke pa-
tients. This primarily consists of regular follow up visits
(frequency as per patient needs) with their stroke neur-
ologist. The standard schedule for clinic visits after an
uncomplicated recovery is 2 weeks, 1 month, 3 months
and 6 months after index stroke. On each clinic visit, a
detailed neurological examination is performed, stroke
risk factors are assessed and concerns and queries are
addressed. In addition, the patient is counseled regarding
beneficial life style modifications and the significance of
compliance with medication regimens. Reading material
about their disease in English or Urdu is offered to each
patient. None of these activities however are extended
beyond their clinic visit. Each patient is, however, pro-
vided with a telephone number that can be used to reach
the stroke team in case of an emergency and each pa-
tient is also reminded of their clinic appointments 1–2
days prior via SMS and/or phone as per center policy.
Intervention group
In addition to the standard of care as provided to the
control group, automated SMS serving as reminders for
patients to take their medicines will be sent to each pa-
tient in the intervention group. These SMS will be sent
at the time patients are scheduled to take their medica-
tions, i.e. once, twice or thrice daily as advised by their
physician. The text will be sent for each dose once, col-
lectively for all drug groups; hence some patients might
receive multiple SMS in a day. The participants will be
required to respond to the SMS stating whether or not
they have taken their medicines for that time. The patient
response will be recorded. No action will be taken if the
patient does not reply to an SMS or if the patient responds
saying that they have not taken the medicine. The patient
will be reached via phone call if he/she fails to respond for
at least 5 consecutive days to identify the reason.
Furthermore, SMS will be sent twice weekly to each pa-
tient in the intervention group that reinforces the import-
ance of taking medications and other healthy behaviors.
These SMS will be customized to each patient’s risk pro-
file and medications by the research team. For example,
some of these SMS will be drug specific i.e. they explain
the benefit of a particular drug and so they will only be
sent to those taking that drug. The SMS will be phrased
using Michie et al’s taxonomy for behavior change inter-
ventions [38]. The health information messages will cover
information about disease, modifiable risk factors, drug in-
formation and importance of optimal drug adherence.
These are 16 different messages, tailored to individual pa-
tients and will be sent over an 8 week period twice weekly.
The set of messages for each patient will be selected at the
time of recruitment and then sent at the scheduled tim-
ings by our IT staff. These messages will change during
the duration of the study for the participant based on their
profile for e.g. a non-smoking participant is not to get a
message about quitting smoking. However for the overall
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study these are standardized messages that have been
worded and coded carefully.
Using the standardized definitions as presented in the
taxonomy allows for easy reproducibility and generalized
applicability for future work related to this intervention.
The specific content of the SMS is derived based on the
Social Cognitive theory [39] and Health Belief model
[40] of behavior change in health care. Templates used
include “Stroke can happen again. Don’t forget to take
your medicine” and “High blood pressure can cause
stroke. Please take your blood pressure medicine.” The
purpose of adapting this model for designing SMS is to
make them effective in communicating to the participants
the consequences of their behavior on health (Fig. 2).
Fig. 2 Screenshots of SMS (Templates)
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Additional file 2 provides details of these SMS along
with the taxonomy number for each SMS design. The
definitions of each taxonomy are also provided in the
appendix.
The Frontline SMS software will be used to send the
SMS. The software has open access and is free to use.
Additional file 3 describes the software usage for this
specific study.
Outcomes
The primary outcome of interest will be a change in
medication adherence after 2 months of receiving the
SMS. These findings will be compared to its correspond-
ing findings from the control group to account for the
Hawthorne effect.
Medication adherence will be measured at recruitment
and after 2 months in both groups on the Morisky
Medication Adherence Scale [18]. The scale has been
used in a similar setting previously and it has been
translated and validated in Urdu [41]. The change will
be determined by comparing the score on the MMAS
before and after the intervention.
The instrument consists of 8 questions and the re-
sponse to each question is scored as either 0 or 1. The
maximum score, hence, through this questionnaire is 8.
A higher score indicates better adherence. A score of < 2
indicates low adherence.
Secondary outcome measures include patient satisfac-
tion and acceptability of using an e-health based
innovation such as the SMS to improve clinical out-
come. This will be done through a tool that has been de-
signed for IT based interventions and adapted for this
study. This tool identifies beneficial and untoward attri-
butes of the SMS for stroke intervention by users. The
tool design for measuring acceptability of innovation is
based on Roger's Diffusion of Innovations theory. The
tool hence has questions that specifically assess the rela-
tive advantage of SMS, its compatibility with the study
population, its complexity, its trialability and observabil-
ity [42].
Participant timeline
Recruitment will begin with signing of an informed
consent and assigning the patient an ID number. Data
collection will begin with a detailed interview regard-
ing the demographic and clinical details of the patient
including his/her prescription details. The baseline
MMAS score for each patient will also be calculated
at this time. This will be followed by the research
staff leaving the room and a senior investigator (QS)
taking over at which point the patient will be ran-
domized to either the intervention or the control
group by the independent CTU staff.
If the patient is allocated to the intervention arm, the
investigator (unblended) will explain the details of the
intervention and will demonstrate by sending one test
SMS on his/her cell phone (in English and Urdu both).
If there is a change in patient prescription with respect
to any drug or dose by any physician, the patient will be
requested to notify at a 24 hours helpline number an-
swered by trained staff. In addition, since participants
are tagged in the hospital system as trial participants all
visits are logged and there will be tracking to ascertain
any changes in prescription which will be medically
confirmed.
Following the recruitment visit, the patients will not
be required to come back to clinic for any additional
visits for the purposes of this study for 2 months at
which time there will be a follow up interview. At this
time, patient adherence will be assessed by the research
officer again who will be blinded.
Duration
The trial will continue till achievement of sample size
and 2 months follow up for outcome ascertainment
thereafter.
Sample size
Based on literature, we estimated the mean MMAS
score to be 6 [43] in the control arm and 7 in the inter-
vention group, giving a mean difference of 1. A standard
deviation of 2 is assumed for this score. Using these
values, a sample of at least 172 subjects will be required
to achieve a power of 90 % and significance level of 5 %
when testing a two tailed hypothesis. This translates into
16 % effect size as hypothesized. Keeping a 15 % attrition
rate the sample size was inflated so that at least 100 sub-
jects will be targeted for each arm in the sample.
Assignment of interventions
Cards with patient assignments to either the interven-
tion or the control group will be prepared by the CTU
through computerized block randomization technique in
block sizes of 10. This is to ensure similarity between
the two groups at all times permitting interim analysis
during the study. Additionally block size was not dis-
cussed with the research team interacting with partici-
pant recruitment to limit predictability of assignment
and researcher bias.
The randomization cards will be sealed in opaque en-
velopes, marked by ID and kept with the CTU. Even if
the envelope is held against bright sunlight one will not
be able to ascertain the allocation. After enrollment,
obtaining informed consent and completing the baseline
measurements, the CTU will be informed and
randomization of the participant will be done.
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Data collection methods
The patients will be asked to come in 2 months later for
a follow up interview to assess the outcome of the trial.
Data will be collected on a Data collection form (DCF)
in this interview by a research officer who will be
blinded to the allocation of the participants. This pri-
marily consists of the MMAS and a tool that assesses
patient satisfaction regarding the SMS innovation.
Participants in both arms will be contacted 2 days
prior to interview as reminders for their appointment.
They will be compensated for their fare for reaching the
center. In case, the participants do not report for their
follow up appointment, they will be contacted and their
appointments will be rescheduled.
Pilot testing
Pilot Testing will be performed on 10 % of the sample
size i.e. 20 patients before commencement of the study.
As per the actual study, participants will be recruited
from Neurology and Stroke Clinics and standard proce-
dures will be followed. This will allow testing the inter-
vention for smooth application and any systematic
errors. Problems (if any) with eligibility criteria will be
identified and the feasibility of achieving sample size will
be assessed. The data collection tool will be assessed for
flow of questions and comprehensiveness. The interven-
tion will be assessed for practicality relating to delivery,
accuracy, timeliness, comprehension and satisfaction.
These participants will be excluded from the final study
sample.
Data management
Research officers will be specifically trained to collect all
data during patient interview leaving no data collection
forms incomplete. All data collected will be sent to the
research office in sealed envelopes. At the end of each
day, any missing data on forms will be noted. In case, of
missing data, the participant will be contacted to fill the
missing information. The data will be entered by a sep-
arate team that is formed for data entry on Microsoft
Access. This team does not include any members in-
volved with research. As per institutional policy, double
entry is mandatory for all data. The data entry operators
will be blinded to the allocation of each patient. All data
entered will be backed up centrally.
Statistical methods
Analysis will be performed using the intention to treat
principle at two stages: interim analysis after 25 % of the
sample has been reached and final analysis after data has
been collected from all study participants. The analysis
will be reported to the project team who will publish the
results in a timely manner. Descriptive statistics will be
reported as mean (with standard deviation) for
continuous variables like age, years of schooling, years
since diagnosis, MMAS score etc. Proportions will be re-
ported for categorical variables like gender, marital sta-
tus, area of residence, employment status, proportion of
patients with depression etc.
The primary endpoint will be the difference in medica-
tion adherence level between the two groups as detected
by the MMAS after 2 months of the intervention.
The acceptability and patient satisfaction of the inter-
vention will be reported through proportions with a
break up for Roger’s factors. In addition, we will be
monitoring the study for participant ‘alert fatigue’ and
withdrawals from the intervention.
All data analysis will be performed on STATA version
12. We plan to apply regression modeling techniques to
control for confounders or other covariates such as
baseline clinical status as calculated by the Modified
Rankin Scale, patient age, the severity of their stroke,
number of medications, caregiver or stroke survivor cell
phone user are all important variables that will be in-
cluded in the data analysis as to how they affect adher-
ence. Sensitivity analyses are planned for caregiver SMS
recipient vs. direct users for response rates to the
intervention.
Ethics and human subjects protection
All patients taking part in the trial will be required to
provide written informed consent at the time of recruit-
ment. Consent forms will be approved by the ERC and
they will be available in English and Urdu. The partici-
pants will have the right to withdraw at any moment
during the study; their inclusion or exclusion from the
study will not affect the usual standard care provided to
them. In addition, all participants will be provided finan-
cial reimbursement for all costs pertaining to follow up
visits and replying to reminder SMS. Participants identi-
fied with depression and dementia will be referred to ap-
propriate physicians for further management.
In addition, special care will be taken to maintain the
confidentiality of the patient's disease. The name of the
institution sending the SMS will not be mentioned in
the SMS, nor will be the patient’s name. In addition, spe-
cial care will be taken to send the health promotional
texts twice weekly at times that do not cause discomfort
to the patient such as late at night.
In days of high security alerts in the city and an-
nounced SMS blackouts, it is planned to send advance
SMS the night before to the participant that there would
not be any SMS the next day to avoid participant anxiety
or uncertainty about continuity of care or reception of
services.
All staff has received Good Clinical Practice (GCP)
training and a face to face training in a 2 day Neuroethics
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course regarding research in the developing world where
all design aspects for this trial were discussed.
The study is approved by the Ethical Review Commit-
tee of the Aga Khan University, Karachi, Pakistan. The
study Ethical Review Number is 2763-Med-ERC-13. Any
changes to the protocol need to be approved by the ERC
before implementation. Monthly reviews on the progress
of the trials will be conducted by the ERC including in-
spection of signed informed consent forms. Although
the trial is intended to last around 3 months, in case trial
duration exceeds 6 months, the ERC will require the
protocol to be resubmitted for review.
Access and dissemination policy
Only the PI and research team will have access to the
study results who will be responsible for publishing in a
timely manner. The funding source will not have any
special access or privileges regarding results before pub-
lication. However since this study is funded by NIH , all
publications will be open access in PubMed Central as
per NIH policy [44].
The ERC and the CTU will be provided access if re-
quired. Safety issues and adverse events will be reported
to the ERC of the Aga Khan University.
Results will be disseminated through scientific jour-
nals, conferences and meetings. They will be available at
https://clinicaltrials.gov as soon as they are finalized.
They will also be shared with concerned departments
and patients.
Discussion
This study protocol presents the design of a randomized
controlled trial using SMS for improving medication ad-
herence in stroke patients.
SMS has been used to increase medication adherence
to HIV medications, polio vaccination and maternal and
child care populations with most of the interventions in
first world populations.
There are several unique aspects to this study. Firstly,
SMS has never been used in a unique high risk stroke
population living in resource strapped settings with mar-
ginal support and poor health literacy. Secondly, the
messages themselves are not just simple knowledge
transfer texts, the wording and the content has been de-
signed by the Health Belief Theory and Social Cognitive
Model. Thirdly, each communication message is informed
by taxonomy and coded for easy replicability of interven-
tion. Fourthly, we use interoperable replicable open access
software. Fifth, each message is highly personalized, tai-
lored to the risk profile, habits and medication prescrip-
tion of each participant. Sixth, our study protocol, design
and methods are robust by study design standards [45, 46]
of centralized randomization, allocation concealment,
blinded assessment, intention to treat analysis, design to
ensure maximum follow up and minimize attrition, staff
training and endpoint assessment.
The major limitation of this study is the choice of
measure of primary outcome i.e. self-report of medica-
tion adherence on Morisky Medication Adherence
Questionnaire. Although this tool has been validated in
Urdu in the country, using assessment tools such as bio-
chemical markers or electronic pill boxes may poten-
tially provide more accurate results. This however isn’t
actually possible because of the complexity of the pre-
scription of a stroke patient; it includes drugs for mul-
tiple risk factors and multiple drugs at a time. Simply
opening an electronic pill box registers a dose as admin-
istered even if the patient takes only two medicines out
of the four he was prescribed for that time thus an elec-
tronic pill box couldn’t capture the data of a complicated
regimen. Running biochemical tests for the each of these
medications would be costly and impractical and require
repeat hospital visits and participant fatigue. Also, the
rationale of IT based intervention in SMS is to cue be-
havior at a distance and ensure adherence, getting pa-
tients to make repeat visits during intervention and
interact with the caregiver may then be more responsible
for adherence than the intervention itself. In addition to
this rationale, we had logistic and resource limitations to
consider when we designed this study and repeated pill
count visits by disabled stroke survivors and caregivers
was not feasible in the realm of this current protocol.
Considering all these pros and cons, we opted for a reply
SMS when the medication was taken by the participant
and the self-reported MMAS. Another limitation is that
this study is designed to study the effect of SMS on ad-
herence, a longitudinal study to report the change in risk
factors via SMS like decrease in blood pressure, choles-
terol and control of glucose, or even a change in end-
point like prevention of stroke or myocardial infarction
would further the science of Information Technology
based intervention. Furthermore, we acknowledge that
we do not know mechanistically which component of
the SMS intervention will have the effect of improving
adherence. However, we targeted the SMS intervention
to cover both intentional non adherence (due to lack of
knowledge, or myths, or attitude, which is the educa-
tional SMS) and unintentional non adherence (due to
cognitive issues, forgetfulness etc., which is the reminder
SMS). These issues are discussed in the clinic but there
is usually not enough time and not enough reminders
and presence to reinforce these messages, thus we have
not aimed to target one kind of SMS over the other, but
to try to increase adherence via SMS by targeting both
components of non-adherence through SMS.
This study will be regionally important. Pakistan, like
other emerging low and middle income countries, faces
non communicable diseases like stroke as its major
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health challenge, so a cheap intervention would have
high impact. The population is uniquely high risk for
stroke given its profile, one in three is hypertensive, one
in four diabetic, with rising rates of depression and sui-
cidality. Currently the country has an electronic database
with a unique identifier number, thus the potential of
reaching mass population for NCD primary prevention
as an extension is possible. Since most out of pocket
catastrophic expenditure on stroke pushes most Pakista-
nis below poverty line, when simple prevention would
have helped, even if the effect size is modest, in a popu-
lation dense area, SMS will still save countless lives. Fu-
ture studies should focus on using SMS to improve
clinically meaningful outcomes like reduction of blood
pressure, control of dyslipidemia and reduction of recur-
rent stroke through effective secondary prevention me-
diated by improved adherence to medications.
Trial status
Ongoing
Additional files
Additional file 1: Data Collection Form. (DOCX 44 kb)
Additional file 2: SMS Text and Coding. (DOCX 30 kb)
Additional file 3: Frontline SMS software. (DOCX 1021 kb)
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